SCHEMBL23713153

SCHEMBL23713153

O=C(NNC(O)C(O)C(F)(F)F)c1ccccc1Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 8/20 0.49
▸ ABCG2 Q9UNQ0 1/20 0.44
▸ MAPK8 P45983 1/20 0.43
▸ PTGS1 P23219 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TAS2R14 Q9NYV8 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ AKR1C3 P42330 1/20 0.41
▸ AKR1C2 P52895 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ YAP1 P46937 1/20 0.40
▸ TEAD4 Q15561 1/20 0.40
▸ TEAD2 Q15562 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ PPARD Q03181 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22556312 0.82 RXFP1 (0.50) RXFP1ABCG2MAPK8PTGS1SMN1; SMN2
SCHEMBL23713154 0.81 RXFP1 (0.41) RXFP1ABCG2MAPK8TAS2R14POLB
SCHEMBL22556325 0.80 RXFP1 (0.50) RXFP1ABCG2MAPK8PTGS1SMN1; SMN2
SCHEMBL22556321 0.78 RXFP1 (0.53) RXFP1ABCG2MAPK8PTGS1SMN1; SMN2
SCHEMBL25541393 0.78 RXFP1 (0.44) RXFP1ABCG2MAPK8TAS2R14AKR1C3
SCHEMBL23713160 0.78 RXFP1 (0.47) RXFP1ABCG2MAPK8PTGS1SMN1; SMN2
SCHEMBL22556346 0.78 RXFP1 (0.48) RXFP1ABCG2MAPK8PTGS1SMN1; SMN2
SCHEMBL22556306 0.78 RXFP1 (0.53) RXFP1ABCG2MAPK8PTGS1SMN1; SMN2
SCHEMBL22571423 0.77 RXFP1 (0.47) RXFP1ABCG2MAPK8PTGS1SMN1; SMN2
SCHEMBL20553269 0.77 RXFP1 (0.58) RXFP1ABCG2MAPK8PTGS1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 RXFP1 3511/4885ABCG2 2985/4885MAPK8 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback